CagriSema: adverse events and evidence limits
In the 68-week phase 3 REDEFINE 1 trial, once-weekly subcutaneous semaglutide 2.4 mg plus cagrilintide 2.4 mg in adults without diabetes with obesity, or overweight with at least one related complication, gastrointestinal adverse events affected 79.6% of the combination group versus 39.9% on placebo: nausea, vomiting, diarrhea, constipation or abdominal pain. The events were mainly transient and mild-to-moderate in severity. [1]
These are data for the pharmaceutical combination at the studied doses, rather than one reaction frequency. The abstract does not establish the safety of the catalog reagent. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Gastrointestinal adverse events overall | Adults without diabetes with obesity, or overweight with at least one related complication; semaglutide 2.4 mg plus cagrilintide 2.4 mg subcutaneously once weekly, 68 weeks (REDEFINE 1) | 79.6% in the combination group versus 39.9% on placebo (very common on the pharmacy scale, ≥10%); mainly transient and mild-to-moderate in severity | [1] |
| Nausea | The same participants | Named among the gastrointestinal events; no separate frequency in the abstract | [1] |
| Vomiting | The same participants | Named among the gastrointestinal events; no separate frequency given | [1] |
| Diarrhea | The same participants | Named among the gastrointestinal events; no separate frequency given | [1] |
| Constipation | The same participants | Named among the gastrointestinal events; no separate frequency given | [1] |
| Abdominal pain | The same participants | Named among the gastrointestinal events; no separate frequency given | [1] |
References
- W Timothy Garvey et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity https://doi.org/10.1056/NEJMoa2502081.